Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging...
RNAi / ASO
CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge
The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...
Novartis Launches Leqvio in China at RMB 9,988 per Shot
Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in...
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in...
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
Sirnaomics’ STP707 siRNA Drug Shows Promising Results in Phase I Solid Tumor Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been...
Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration...
AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...
Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...
Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential
Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...
CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890
The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...
Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09
China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to...
Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G
Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...
Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis
China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed...
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou,...
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G
Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...
Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA
Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by...
Olipharma Secures Funding for Manufacturing Expansion in Pre-Series A+ Round
Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and...
Olipharma Raises Funds in Pre-Series A+ Round to Expand Manufacturing Facilities
Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou,...